{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:17:11Z","timestamp":1795133831013,"version":"4.10.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1102752"],"award-info":[{"award-number":["APP1102752"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1136680"],"award-info":[{"award-number":["APP1136680"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1102752"],"award-info":[{"award-number":["APP1102752"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2011391"],"award-info":[{"award-number":["APP2011391"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["MCRF15023"],"award-info":[{"award-number":["MCRF15023"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["TP834128"],"award-info":[{"award-number":["TP834128"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR)\u00a0T cells have transformed the treatment landscape for hematological malignancies. However, CAR T cells are less efficient against solid tumors, largely due to poor infiltration resulting from the immunosuppressive nature of the tumor microenvironment (TME). Here, we assessed the efficacy of Lewis Y antigen (Le<jats:sup>Y<\/jats:sup>)-specific CAR T cells in patient-derived xenograft (PDX) models of prostate cancer. In vitro, Le<jats:sup>Y<\/jats:sup> CAR T cells directly killed organoids derived from androgen receptor (AR)-positive or AR-null PDXs. In vivo, although Le<jats:sup>Y<\/jats:sup> CAR T cells alone did not reduce tumor growth, a single prior dose of carboplatin reduced tumor burden. Carboplatin had a pro-inflammatory effect on the TME that facilitated early and durable CAR T cell infiltration, including an altered cancer-associated fibroblast phenotype, enhanced extracellular matrix degradation and re-oriented M1 macrophage differentiation. In a PDX less sensitive to carboplatin, CAR T cell infiltration was dampened; however, a reduction in tumor burden was still observed with increased T cell activation. These findings indicate that carboplatin improves the efficacy of CAR T cell treatment, with the extent of the response dependent on changes induced within the TME.<\/jats:p>","DOI":"10.1038\/s41467-023-40852-3","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:01:42Z","timestamp":1693659702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models"],"prefix":"10.1038","volume":"14","author":[{"given":"L. H.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4416-7040","authenticated-orcid":false,"given":"J. J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Keerthikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Quezada","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-5887","authenticated-orcid":false,"given":"P. J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-9561","authenticated-orcid":false,"given":"P. K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-2380","authenticated-orcid":false,"given":"R. A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-4028","authenticated-orcid":false,"given":"G. P.","family":"Risbridger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"40852_CR1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2019.08.014","volume":"77","author":"AA Gorchakov","year":"2020","unstructured":"Gorchakov, A. A., Kulemzin, S. V., Kochneva, G. V. & Taranin, A. V. Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer. Eur. Urol. 77, 299\u2013308 (2020).","journal-title":"Eur. Urol."},{"key":"40852_CR2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"40852_CR3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"40852_CR4","doi-asserted-by":"publisher","unstructured":"Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aaw2293 (2019).","DOI":"10.1126\/scitranslmed.aaw2293"},{"key":"40852_CR5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","volume":"18","author":"J Alzubi","year":"2020","unstructured":"Alzubi, J. et al. PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol. Ther. Oncolytics 18, 226\u2013235 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"40852_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0741-7","volume":"7","author":"G Schepisi","year":"2019","unstructured":"Schepisi, G. et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J. Immunother. Cancer 7, 258 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"40852_CR7","doi-asserted-by":"publisher","unstructured":"Murad, J. P. et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2021.02.024 (2021).","DOI":"10.1016\/j.ymthe.2021.02.024"},{"key":"40852_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41591-022-01742-1","volume":"28","author":"NP Tschernia","year":"2022","unstructured":"Tschernia, N. P., Norberg, S. M. & Gulley, J. L. CAR T cells reach clinical milestone in prostate cancer. Nat. Med. 28, 635\u2013636 (2022).","journal-title":"Nat. Med."},{"key":"40852_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","volume":"26","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. Mol. Ther. - Oncolytics 26, 189\u2013206 (2022).","journal-title":"Mol. Ther. - Oncolytics"},{"key":"40852_CR10","doi-asserted-by":"crossref","first-page":"19051","DOI":"10.1073\/pnas.0504312102","volume":"102","author":"JA Westwood","year":"2005","unstructured":"Westwood, J. A. et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl Acad. Sci. USA 102, 19051\u201319056 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"40852_CR11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0022-5347(01)67464-0","volume":"153","author":"RB Myers","year":"1995","unstructured":"Myers, R. B., Srivastava, S. & Grizzle, W. E. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J. Urol. 153, 1572\u20131574 (1995).","journal-title":"J. Urol."},{"key":"40852_CR12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/(SICI)1097-0045(19980801)36:3<162::AID-PROS3>3.0.CO;2-J","volume":"36","author":"Z Culig","year":"1998","unstructured":"Culig, Z. et al. Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. Prostate 36, 162\u2013167 (1998).","journal-title":"Prostate"},{"key":"40852_CR13","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122\u20132129 (2013).","journal-title":"Mol. Ther."},{"key":"40852_CR14","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"40852_CR15","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822\u20131826 (2011).","journal-title":"J. Clin. Invest."},{"key":"40852_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.omto.2020.07.005","volume":"18","author":"A Klampatsa","year":"2020","unstructured":"Klampatsa, A. et al. Analysis and augmentation of the immunologic bystander effects of CAR T cell therapy in a syngeneic mouse cancer model. Mol. Ther. Oncolytics 18, 360\u2013371 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"40852_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CAD.0000000000001248","volume":"33","author":"M Xin","year":"2022","unstructured":"Xin, M. et al. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model. Anticancer Drugs 33, 117\u2013123 (2022).","journal-title":"Anticancer Drugs"},{"key":"40852_CR18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S. et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39, 193\u2013208.e110 (2021).","journal-title":"Cancer Cell"},{"key":"40852_CR19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","volume":"23","author":"CS Lo","year":"2017","unstructured":"Lo, C. S. et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin. Cancer Res. 23, 925\u2013934 (2017).","journal-title":"Clin. Cancer Res."},{"key":"40852_CR20","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","volume":"22","author":"S B\u00f6hm","year":"2016","unstructured":"B\u00f6hm, S. et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin. Cancer Res. 22, 3025\u20133036 (2016).","journal-title":"Clin. Cancer Res."},{"key":"40852_CR21","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics 12, 4965\u20134979 (2022).","journal-title":"Theranostics"},{"key":"40852_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2020.11.049","volume":"500","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 500, 163\u2013171 (2021).","journal-title":"Cancer Lett."},{"key":"40852_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25175-5","volume":"12","author":"GP Risbridger","year":"2021","unstructured":"Risbridger, G. P. et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat. Commun. 12, 5049 (2021).","journal-title":"Nat. Commun."},{"key":"40852_CR24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","volume":"28","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. 28, 2379\u20132393 (2020).","journal-title":"Mol. Ther."},{"key":"40852_CR25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"40852_CR26","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2019","unstructured":"Jayasingam, S. D. et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front. Oncol. 9, 1512 (2019).","journal-title":"Front. Oncol."},{"key":"40852_CR27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).","journal-title":"Front. Immunol."},{"key":"40852_CR28","doi-asserted-by":"crossref","first-page":"e0145342","DOI":"10.1371\/journal.pone.0145342","volume":"10","author":"KA Jablonski","year":"2015","unstructured":"Jablonski, K. A. et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS ONE 10, e0145342 (2015).","journal-title":"PLoS ONE"},{"key":"40852_CR29","doi-asserted-by":"publisher","unstructured":"Sebastian, A. et al. Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12051307 (2020).","DOI":"10.3390\/cancers12051307"},{"key":"40852_CR30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir, A. et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40, 318\u2013334.e319 (2022).","journal-title":"Cancer Cell"},{"key":"40852_CR31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00001813-199212000-00017","volume":"3","author":"JP Palma","year":"1992","unstructured":"Palma, J. P., Aggarwal, S. K. & Jiwa, A. Murine macrophage activation after cisplatin or carboplatin treatment. Anticancer Drugs 3, 665\u2013676 (1992).","journal-title":"Anticancer Drugs"},{"key":"40852_CR32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00001813-199412000-00002","volume":"5","author":"JP Palma","year":"1994","unstructured":"Palma, J. P. & Aggarwal, S. K. Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro. Anticancer Drugs 5, 615\u2013622 (1994).","journal-title":"Anticancer Drugs"},{"key":"40852_CR33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487\u2013504 (2020).","journal-title":"Clin. Cancer Res."},{"key":"40852_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu, E. Y. et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur. Urol. 82, 22\u201330 (2022).","journal-title":"Eur. Urol."},{"key":"40852_CR35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao, P., Li, L., Jiang, X. & Li, Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J. Hematol. Oncol. 12, 54 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"40852_CR36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.annonc.2021.07.018","volume":"32","author":"D Meyran","year":"2021","unstructured":"Meyran, D. et al. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann. Oncol. 32, 1366\u20131380 (2021).","journal-title":"Ann. Oncol."},{"key":"40852_CR37","doi-asserted-by":"crossref","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"D Meyran","year":"2023","unstructured":"Meyran, D. et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci. Transl. Med. 15, eabk1900 (2023).","journal-title":"Sci. Transl. Med."},{"key":"40852_CR38","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"40852_CR39","doi-asserted-by":"publisher","unstructured":"Dorff, T. B. et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1483 (2021).","DOI":"10.1158\/1078-0432.CCR-21-1483"},{"key":"40852_CR40","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nbt.3674","volume":"34","author":"K Alsop","year":"2016","unstructured":"Alsop, K. et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat. Biotechnol. 34, 1010\u20131014 (2016).","journal-title":"Nat. Biotechnol."},{"key":"40852_CR41","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477\u20136489 (2005).","journal-title":"J. Immunol."},{"key":"40852_CR42","first-page":"3254","volume":"60","author":"AM Scott","year":"2000","unstructured":"Scott, A. M. et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 60, 3254\u20133261 (2000).","journal-title":"Cancer Res."},{"key":"40852_CR43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/CJI.0b013e31819b7c8e","volume":"32","author":"JA Westwood","year":"2009","unstructured":"Westwood, J. A. et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunother. 32, 292\u2013301 (2009).","journal-title":"J. Immunother."},{"key":"40852_CR44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/24725552211020668","volume":"26","author":"N Choo","year":"2021","unstructured":"Choo, N. et al. High-throughput imaging assay for drug screening of 3D prostate cancer organoids. SLAS Discov. 26, 1107\u20131124 (2021).","journal-title":"SLAS Discov."},{"key":"40852_CR45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"40852_CR46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1083\/jcb.201004104","volume":"189","author":"M Linkert","year":"2010","unstructured":"Linkert, M. et al. Metadata matters: access to image data in the real world. J. Cell Biol. 189, 777\u2013782 (2010).","journal-title":"J. Cell Biol."},{"key":"40852_CR47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","volume":"4","author":"S Agrawal","year":"2016","unstructured":"Agrawal, S., Feng, Y., Roy, A., Kollia, G. & Lestini, B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J. Immunother. Cancer 4, 72 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"40852_CR48","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/2326-6066.CIR-18-0874","volume":"7","author":"IM Meraz","year":"2019","unstructured":"Meraz, I. M. et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol. Res. 7, 1267\u20131279 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"40852_CR49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148\u2013154 (1989).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"40852_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman, A. et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat. Commun. 12, 3015 (2021).","journal-title":"Nat. Commun."},{"key":"40852_CR51","doi-asserted-by":"publisher","unstructured":"Cheloni, S., Hillje, R., Luzi, L., Pelicci, P. G. & Gatti, E. XenoCell: classification of cellular barcodes in single cell experiments from xenograft samples. bioRxiv https:\/\/doi.org\/10.1101\/679183 (2019).","DOI":"10.1101\/679183"},{"key":"40852_CR52","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1670-y","volume":"20","author":"A Srivastava","year":"2019","unstructured":"Srivastava, A., Malik, L., Smith, T., Sudbery, I. & Patro, R. Alevin efficiently estimates accurate gene abundances from dscRNA-seq data. Genome Biol. 20, 65 (2019).","journal-title":"Genome Biol."},{"key":"40852_CR53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"40852_CR54","doi-asserted-by":"publisher","unstructured":"Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience https:\/\/doi.org\/10.1093\/gigascience\/giy083 (2018).","DOI":"10.1093\/gigascience\/giy083"},{"key":"40852_CR55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-020-01625-6","volume":"4","author":"N Borcherding","year":"2021","unstructured":"Borcherding, N. et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun. Biol. 4, 122 (2021).","journal-title":"Commun. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40852-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:09:05Z","timestamp":1700186945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40852"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40852-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P.R. and R.A.T. (Research collaborations: Pfizer, Astellas, Zenith Epigenetics, AstraZeneca); P.K.D. (Research funding from Myeloid Therapeutics, Prescient Therapeutics, and Bristol Myers Squibb); A.A. (Speakers Bureau: Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer; Honoraria: Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome; Scientific Advisory Board: Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm; Travel + Accommodation: Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Investigator Research Funding: Astellas, Merck Serono, AstraZeneca; Institutional Research Funding: Bristol Myers Squibb, AstraZeneca, Aptevo Therapeutics, Glaxo Smith Kline, Pfizer, MedImmune, Astellas, SYNthorx, Bionomics, Sanofi Aventis, Novartis, Ipsen); M.S.H. (personal fees for lectures or advisory boards: Jannsen, Mundipharma, Astellas, Merck\/MSD, Astra Zeneca, Point Biopharma; Research support paid to institution: Endocyte and Advanced Accelerator Applications, both Novartis companies); I.V. (Honoraria: Astellas, Abbvie, Tolmar, Janssen; Scientific Advisory Board: Astellas, AstraZeneca, Janssen, Bayer); P.J.N. (Research funding from BMS, Roche Genentech, MSD, Prescient Therapeutics, CRISPR Therapeutics, Allergan, Compugen); All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5346"}}